Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

Inclusion Criteria: * Age range from 18 to 75 years old, both male and female. * Confirmed definite IIH with papilledema and lumbar opening pressure ≥25 cm cerebrospinal fluid according to Friedmann diagnostic criteria. * Voluntarily sign a written informed consent form. Exclusion Criteria: * Pregnant or breastfeeding women. * Currently using any hypoglycemic drugs, including glucagon like peptide-1 receptor agonists. * Known to be allergic to the active ingredients or any excipients in Semaglutide. * History or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasias (MEN1/MEN2). * Diabetes, ketoacidosis, severe gastrointestinal diseases, pancreatitis, severe heart failure. * Vision loss caused by other diseases, such as diabetes retinopathy, iritis, cataract, etc. * Malignant IIH with vision at risk necessitating surgical intervention. * Unable to cooperate in completing imaging examinations. * History of bariatric surgery or cerebrospinal fluid diversion. * Have used any drugs known to increase intracranial pressure within the past 3 months (including vitamin A, tetracycline drugs, lithium, etc). * Have participated in other clinical trials within the past 3 months, or did not withdraw from other clinical trials at the time of signing the informed consent form. * Other situations determined by the researcher that may pose a threat to the patients' life safety or may have an impact on the study.